Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Open Access
- 15 August 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (4), 1174-1182
- https://doi.org/10.1182/blood-2005-09-008086
Abstract
We studied the cellular and molecular effects of the combination of an anthracycline with 2 different histone deacetylase inhibitors (HDACIs): vorinostat (suberoylanilide hydroxamic acid) and valproic acid (VPA). The 10% inhibitory concentration (IC10) of idarubicin was 0.5 nM in MOLT4 and 1.5 nM in HL60 cells. Concentrations above 0.675 μM of vorinostat resulted in at least 80% loss of cell viability in both cell lines. Concentrations of 1.5 to 3 mM of VPA induced 50% to 60% loss in viability in HL60 and 80% in MOLT4 cells. The combination of idarubicin with vorinostat at 0.075 μM or VPA at 0.25 mM resulted in at least an additive loss of cell viability in both lines. Vorinostat (0.35 μM) and VPA (0.25 mM) in combination with idarubicin (0.5 nM) resulted in a significant increase in apoptotic cells in MOLT4 cells. The combination resulted in an increase in histone H3 and H4 acetylation at 24 hours, phosphorylated H2AX, as well as in the induction of p21CIP1 mRNA. No effect on cell cycle transition was observed. Of importance, the cellular and molecular effects observed were independent of the sequence used. In summary, the combination of an anthracycline with an HDACI should have significant clinical activity in patients with leukemia.Keywords
This publication has 26 references indexed in Scilit:
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic AgentsCancer Investigation, 2005
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood, 2004
- Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidBlood, 2004
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood, 2004
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275Cancer Research, 2004
- Characteristics of γ-H2AX foci at DNA double-strand breaks sitesBiochemistry and Cell Biology, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Deacetylase Activity Associates with Topoisomerase II and Is Necessary for Etoposide-induced ApoptosisPublished by Elsevier BV ,2001